Enlivex Therapeutics Ltd
NASDAQ:ENLV

Watchlist Manager
Enlivex Therapeutics Ltd Logo
Enlivex Therapeutics Ltd
NASDAQ:ENLV
Watchlist
Price: 1.23 USD -0.81%
Market Cap: 27m USD
Have any thoughts about
Enlivex Therapeutics Ltd?
Write Note

Enlivex Therapeutics Ltd
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Enlivex Therapeutics Ltd
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Enlivex Therapeutics Ltd
NASDAQ:ENLV
Depreciation & Amortization
$762k
CAGR 3-Years
22%
CAGR 5-Years
80%
CAGR 10-Years
N/A
Collplant Biotechnologies Ltd
NASDAQ:CLGN
Depreciation & Amortization
$1.1m
CAGR 3-Years
19%
CAGR 5-Years
27%
CAGR 10-Years
N/A
Kamada Ltd
NASDAQ:KMDA
Depreciation & Amortization
$12.9m
CAGR 3-Years
38%
CAGR 5-Years
25%
CAGR 10-Years
17%
Urogen Pharma Ltd
NASDAQ:URGN
Depreciation & Amortization
$453k
CAGR 3-Years
-15%
CAGR 5-Years
12%
CAGR 10-Years
N/A
B
Bonus Biogroup Ltd
TASE:BONS
Depreciation & Amortization
â‚Ş2.8m
CAGR 3-Years
44%
CAGR 5-Years
34%
CAGR 10-Years
21%
Pluri Inc
NASDAQ:PLUR
Depreciation & Amortization
$251k
CAGR 3-Years
-43%
CAGR 5-Years
-33%
CAGR 10-Years
-18%
No Stocks Found

Enlivex Therapeutics Ltd
Glance View

Market Cap
25.7m USD
Industry
Biotechnology

Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.

ENLV Intrinsic Value
1.18 USD
Overvaluation 4%
Intrinsic Value
Price

See Also

What is Enlivex Therapeutics Ltd's Depreciation & Amortization?
Depreciation & Amortization
762k USD

Based on the financial report for Jun 30, 2024, Enlivex Therapeutics Ltd's Depreciation & Amortization amounts to 762k USD.

What is Enlivex Therapeutics Ltd's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
80%

Over the last year, the Depreciation & Amortization growth was -9%. The average annual Depreciation & Amortization growth rates for Enlivex Therapeutics Ltd have been 22% over the past three years , 80% over the past five years .

Back to Top